Entera Bio (ENTX) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Entera Bio (ENTX) has outperformed Kyverna Therapeutics (KYTX) over the past year, gaining 15.2% versus a loss of 13.9%. Entera Bio is the larger company by market cap ($445.9 million vs $386.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTX | KYTX |
|---|---|---|
| Share price | $2.57 | $6.25 |
| Market cap | $445.88M | $386.52M |
| 1-day change | +2.60% | +1.14% |
| YTD return | +28.87% | -34.26% |
| 1-year return | +15.21% | -13.93% |
| 5-year return | -44.69% | — |
| EPS (TTM) | $-0.36 | $-2.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.20 | $13.67 |
| 52-week low | $0.91 | $5.96 |
| Distance from 52-week high | -38.93% | -54.28% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +280.12% | +386.40% |
| Average volume | 1.82M | 903.83K |
| Shares outstanding | 173.83M | 61.84M |
| Employees | 20 | 149 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTX has outperformed KYTX by 29.1 percentage points over the past year.
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
ENTX vs KYTX FAQ
Which is bigger, Entera Bio or Kyverna Therapeutics?
Entera Bio (ENTX) is larger, with a market capitalization of $445.88M compared with $386.52M for Kyverna Therapeutics (KYTX).
Which stock has performed better over the past year, ENTX or KYTX?
ENTX returned +15.21% over the past 12 months, compared with -13.93% for KYTX (price return, excluding dividends). Past performance does not predict future results.
Are Entera Bio and Kyverna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.